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HUMAN PLACENTA-DERIVED STEM CELL S (HPDSC) AUGMENT TRANS-
PLANTATION WITH UMBILICAL CORD BLOOD
Yu, L.C.1, Faleck, H.2, Johnson, K.2, Payne, D.2, Hariri, R.2 1 Children’s
Hospital/LSUHSC, New Orleans, LA; 2 Celgene, Warren, NJ
This is the first report of a patient treated in a single-arm,
non-randomized pilot study to assess the safety of human placenta-
derived stem cells (HPDSC) transplantation with partially- or
fully- HLA matched, related-donor umbilical cord blood (UCB)
for malignant or non-malignant disorders requiring stem cell trans-
plantation. HPDSC is being developed by Celgene Cellular Thera-
peutics (CCT) to augment the UCB stem cell graft. HPDSC is
obtained by CCT’s proprietary process involving perfusion of pla-
cental vasculature and is processed to remove red blood cells, non-vi-
able cells and tissue debris. HPDSC is enriched in CD341 cells and
other progenitor cell types. Non-clinical studies have shown that
augmenting a UCB transplant with HPDSC results in a higher likeli-
hood of successful engraftment and an earlier engraftment as com-
pared to UCB alone or HPDSC alone. It is hypothesized that the
infusion of HPDSC following UCB transplantation will improve
transplant outcome, shorten the time to neutrophil and/or platelet
engraftment and diminish serious complications of the transplant
procedure. The first patient is a 5 year old, 24 kg male with very
high risk ALL in first remission. The subject underwent standard
full ablative conditioning. GVHD prophylaxis consisted of steroids
and cyclosporine. The subject was transplanted with a UCB unit
(596.20  106 TNC, 73% post-thaw viability, 0.26% CD341) and
HPDSC unit (294  106 TNC, 63% post thaw viability, 0.85%
CD341) obtained from his HLA-matched sibling and processed/
stored by LifeBankUSA, a wholly owned subsidiary of Celgene
Corp. There were no clinically significant infusion reactions, and
to date there have been no HPDSC-related serious adverse events.
Myeloid engraftment occurred by Day117 and platelet engraftment
by Day170. There was no evidence of serious infection nor
aGVHD. Complete donor chimerism was evident by Day130.
The subject was discharged from the hospital on day 115. Subject
is disease-free for more than 6 months post-transplant and his im-
mune system is recovering as expected. Based upon this initial expe-
rience, infusion of HPDSC was safe and may have therapeutic
benefit in augmenting cord blood transplantation. Continuation of
the study is warranted.132
A HIGH INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN
UNRELATED CORD BLOOD TRANSPLANTATION IN PAEDIATRIC
PATIENTS – A SINGLE CENTRE EXPERIENCE
Chan, L.A., Abdullah, W.A., Chong, L.A., Ariffin, H. University Malaya
Medical Centre, Kuala Lumpur, Malaysia
Introduction: Haematopoietic stem cell transplantation (HSCT)
is the treatment of choice for certain malignant and inherited disor-
ders in paediatric patients. The use of unrelated cord blood (UCB) as
a stem cell source presents advantages which include immediate
availability, less stringent HLA matching and less graft-versus-host
disease (GVHD). Grade II to IV aGVHD has been reported to be
between 14 to 36% in HLA 2/6 mismatched UCBT. We report
a much higher incidence of aGVHD.
Materials: From 1997 till 2008, single UCB units from various in-
ternational cord blood banks were imported for 31 patients. Indica-
tions for transplantation included ALL in 9 pts, AML 4, JMML 3,
CML in CP 1, SAA 1, Thalassaemia 8 , Wiskott-Aldrich syndrome
2 and Osteopetrosis 3. Cord blood units were 3,4, 5 or 6 HLA
matched units for 1, 18, 9 and 3 recipients consecutively. Condition-
ing regimen for ALL included TBI and CY6 ATG6Thiotepa. Pa-
tients with AML received BU and CY6ATG while the majority of
non-malignant disorders were conditioned with BU1CY1ATG.
Prophylaxis against GVHD used cyclosporine(CSA) with low dose
MTX or prednisolone or CSA alone. Treatment of GVHD included
methyprednisolone, ATG, MMF and infliximab.
Results: The median age was 5 years (range 0.7–13 years) and
weight was 17.5 kg (5.56–50.2 kg). Median nucleated cell dose was
8.7  107/kg (range 2.6–29.3) while median CD341 cell dose was
2.6  105/kg (range 0.48–12.2). Four patients were early deaths
and not evaluable for engraftment. Twenty out of 27 pts (74%) expe-rienced neutrophil engraftment at a median of D25 (range 12–36)
and platelet.20K at a median of D46 (36–183) while primary graft
failure occurred in 7 pts (26%). AGVHD occurred in 19/20 pts with
clinical grades I, II, III and IV occurring in 1,7,7 and 4 pts respec-
tively. Of the 11 pts with grades III and IV aGVHD (55%), 3 were
alive while 8 succumbed to infection or multiorgan failure. Chronic
GVHD occurred in 3/13 evaluable pts where 1 was extensive. VOD
occurred in 9 pts. Mortality occurred in 17/31 pts (55%). Survival
was seen in 14 pts (45%) with follow up from 5–95 months.
Conclusion: We experienced a 95% incidence of aGVHD and
more than half of them were severe clinical grade III and IV which
directly contributed to mortality of patients.133
OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HCT) FROM UMBILICAL CORD BLOOD (UCB) UNITS IN PATIENTS
WITH MALIGNANT AND NON-MALIGNANT DISORDERS
Pawlowska, Bolotin, Mai-ton, Senitzer, Dagis, Wang, Zlotnicki, Forman,
Rosenthal City of Hope, Duarte, CA
HCT is a curative treatment option for high risk malignant and
non-malignant diseases. HLA-identical donors are the preferred
graft sources. Matched unrelated donors have been utilized success-
fully for the last two decades. However, in about 30% of all patients
neither an HLA-matched sibling nor a MUD donor is available; for
these patients UCB has become an acceptable stem cell source. UCB
offers several advantages: rapid availability, the possibility of using
HLA-mismatched units and a decreased risk of GVHD. We ana-
lyzed the treatment outcomes in patients who have undergone
HCT using UCB at City of Hope. 45 patients with malignant
(82%) and non-malignant (18%) hematological disorders received
46 HCT using allogeneic or autologous UCB from January 1,
1997 through June 31, 2007. 29 patients (66%) carried a diagnosis
of acute leukemia. 36 patients received single cord unit (including
2 autologous transplants), 10 patients received two UCB units.
80% of patients were alive at day 100. 1 year and estimated 5-year
overall survival (0S) was 53% (95% CI 38%–89%) and 43% (95%
CI 28%–64%) respectively with median follow up of patients alive
at date of analysis of 4.2 years. Estimated 5-year survival for single
(excluding autologous), double and autologous UCB transplant
was 44% (95% CI 27%–60%), 28% (95% CI 4%–59%) and 100%
respectively. Degree of HLA mismatch impacted OS – patients
receiving UCB mismatched at 0 or 1 loci had significantly better
5-year survival (61%, 95% CI 40%–77%) compared to patients
transplanted with 2 to 3 antigen mismatched units (17% 95% CI
4%–36%) p 5 0.005. Neutrophil engraftment occurred at median
26 days (89% of patients engrafted by day 53). The incidence and
time to platelet engraftment to 20K and 50K was 76% (median
50.5 days) and 67% (median 69 days) respectively. 62% of patients
receiving single UCB developed acute GVHD (44% grade 1–2;
18% grade 3–4). 23% of these patients developed chronic GVHD
(20% limited, 3% severe). All patients who received two UCB units
developed acute GVHD (80% grade 1–2, 20% grade 3–4; and later
chronic GVHD). 14 patients (30%) developed CMV infection (4
prior to day 30, 7 within days 30–100, 3 post day 100). 26% of pa-
tients had culture proven viral infections. In conclusion, for patients
with high risk disease lacking HLA-matched sibling donor, UCB can
offer a rapidly available alternative source of stem cells with trans-
plant outcomes comparable to the results achieved using matched
unrelated donors.LATE EFFECTS/QUALITY OF LIFE
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DIABETES MELLITUS (DM) AND HYPERTENSION (HTN) IN ADULT
AND PEDIATRIC SURVIVORS OF ALLOGENEIC HEMATOPOIETIC-CELL
TRANSPLANTATION (HCT)
Majhail, N.S., Challa, T.R., Mulrooney, D.A., Baker, K.S., Burns, L.J.
University of Minnesota, Minneapolis, MN
DM and HTN are frequent early complications of allogeneic
HCT; however, their long-term outcome is not well known. We
